List of Excipients in Branded Drug LYUMJEV

« Back to Dashboard

Last updated: August 10, 2026

ecutive summary: Lyumjev is Eli Lilly’s ultra-rapid insulin lispro formulation, differentiated by absorption-enhancing excipients rather than a new insulin sequence. Its commercial value depends on rapid postprandial control, compatibility with insulin pumps and pens, and protection of the formulation platform. The core excipient opportunity is concentrated in citrate and treprostinil, which accelerate subcutaneous absorption, supported by conventional insulin excipients such as glycerol, metacresol, zinc, magnesium, and tromethamine. Suppliers that can provide sterile, low-impurity, pharmacopeial-grade components, formulation analytics, and device-compatible fill-finish services have the strongest opportunity.

LYUMJEV excipient strategy, patent position, and commercial opportunities

What is Lyumjev and how do its excipients create differentiation?

Lyumjev is insulin lispro-aabc, an ultra-rapid-acting formulation developed by Eli Lilly and Company. The product is administered by subcutaneous injection and is available in U-100 and U-200 presentations. It is intended for mealtime dosing and has also been approved for use in compatible continuous subcutaneous insulin infusion systems, subject to product-specific instructions.[1]

Lyumjev uses the same insulin lispro amino-acid sequence as Humalog but changes the delivery environment around the insulin molecule. The formulation includes absorption-enhancing components that reduce the delay between injection and systemic insulin exposure. Lilly’s clinical pharmacology materials identify citrate and treprostinil as components that accelerate absorption.[1,2]

The formulation strategy addresses a persistent limitation of conventional rapid-acting insulin: insulin absorption remains slower than normal physiologic insulin secretion after a meal. Lyumjev is designed to narrow that gap during the first 30 minutes after dosing.

Formulation element	Primary function	Commercial relevance
Insulin lispro	Active insulin analog	Defines biological activity and dose
Citrate	Absorption-enhancing component and formulation control agent	Potential target for formulation replication and supply
Treprostinil	Local absorption-enhancing component	High-value specialty excipient with regulatory and safety controls
Glycerol	Tonicity and stabilizing agent	Established injectable excipient
Metacresol	Preservative	Important for multidose vials, cartridges, and pens
Magnesium chloride	Ionic and formulation-support role	Low-dose, quality-sensitive component
Tromethamine	Buffering and pH control	Supports stability and injection compatibility
Zinc oxide	Insulin stabilization and hexamer-related behavior	Relevant to aggregation, potency, and release testing
Hydrochloric acid and sodium hydroxide	pH adjustment	Standard process inputs
Water for injection	Vehicle	Sterile manufacturing requirement

The commercial differentiator is not the use of ordinary excipients such as glycerol or metacresol. It is the controlled combination of absorption enhancement, insulin stabilization, preservative performance, pH, ionic strength, and device delivery.

Which excipients are most important in the Lyumjev formulation?

Citrate

Citrate is associated with faster insulin absorption after subcutaneous administration. It can alter the local injection-site environment and influence insulin diffusion away from the depot. Its concentration, pH interaction, ionic strength, and compatibility with the insulin molecule require tight control.

For suppliers, citrate is a relatively accessible component. The opportunity is stronger in validated pharmaceutical-grade supply, low-bioburden production, endotoxin control, and reliable lot-to-lot performance than in simple bulk manufacture.

Treprostinil

Treprostinil is the strategically important excipient in Lyumjev. It is a prostacyclin analog used clinically in other settings, including pulmonary arterial hypertension. In Lyumjev, it is used at a low local concentration to promote faster absorption of insulin lispro.[1,2]

Treprostinil creates a higher barrier to competitive replication than conventional buffers. A supplier or licensee must address:

• Active pharmaceutical ingredient or specialty-excipient manufacturing controls
• Impurity and degradant profiling
• Residual solvent and elemental impurity limits
• Sterile formulation compatibility
• Local tolerability
• Stability in combination with insulin lispro
• Device-contact material compatibility
• Regulatory classification as an inactive or functionally active formulation component

Treprostinil also creates a potential supply-chain bottleneck. A formulation competitor may reproduce the absorption concept without using treprostinil, but the substitute must demonstrate comparable pharmacokinetics, tolerability, stability, and clinical performance.

Zinc and magnesium

Zinc supports insulin association and stabilization. Magnesium chloride can influence ionic strength and protein behavior. These components are present at low concentrations, but small changes can affect aggregation, potency, particulate formation, and release testing.

Their commercial opportunity lies in high-purity injectable grades, not commodity volume. Suppliers with elemental impurity control, narrow particle specifications, and validated compendial testing have an advantage.

Metacresol

Metacresol is a conventional preservative used in multidose insulin products. It supports microbiological integrity after repeated vial or cartridge access. Its concentration must balance preservative effectiveness with local tolerability.

Metacresol is unlikely to create standalone protection for Lyumjev. It remains important for generic or biosimilar developers because preservative differences can affect stability, extractables, container closure, and in-use dating.

What formulations are protected by Lyumjev’s intellectual-property strategy?

The commercially relevant protection is expected to center on composition, method of use, absorption enhancement, and delivery-system integration rather than on the insulin lispro sequence alone.

Formulation patents

Formulation claims may cover combinations of:

• Insulin lispro or related rapid-acting insulin analogs
• Citrate or other absorption-enhancing buffers
• Treprostinil or related prostacyclin-pathway agents
• Specific concentration ranges
• pH and ionic-strength windows
• Stabilizers and preservatives
• Reduced time to insulin exposure
• Compatibility with pen, cartridge, vial, or pump systems

The key risk for a competitor is that a composition claim may cover a concentration range broad enough to capture a clinically useful substitute. A narrow design-around may avoid literal infringement but still create regulatory and clinical-development costs.

Method-of-use patents

Potential method claims can address:

• Administration at or near mealtime
• Improved early postprandial glucose control
• Use in insulin pumps
• Reduction in postprandial glucose excursions
• Dosing immediately before or shortly after meals
• Specific use in adults or pediatric patients
• Use in patients requiring intensive insulin therapy

Method-of-use claims are commercially relevant even when a competitor can formulate a similar insulin. Their enforceability depends on labeling, prescribing behavior, induced-infringement facts, and the exact scope of the issued claims.

Device and container-closure protection

Lyumjev is delivered through insulin pens, cartridges, vials, and pump systems. The formulation must remain stable in contact with elastomers, plastics, adhesives, and device reservoirs. Related intellectual property may cover:

• Pen or cartridge geometry
• Dose delivery accuracy
• U-200 delivery configurations
• Pump-reservoir compatibility
• Material selection
• Extractables and leachables control
• In-use stability

This protection can create practical barriers even when a competing formulation is chemically similar.

What is the FDA regulatory status of Lyumjev?

Lyumjev was approved by the U.S. Food and Drug Administration in June 2020 for adults with diabetes.[3] The FDA later expanded labeling to pediatric patients aged one year and older.[4]

The product is an insulin biologic and is regulated within the FDA’s insulin and biological-product framework. Since March 23, 2020, insulin products historically approved under the Federal Food, Drug, and Cosmetic Act have transitioned to regulation under the Public Health Service Act.[5]

This regulatory status affects competitive entry. A conventional small-molecule ANDA is not the expected pathway for a follow-on version of Lyumjev. A competitor would generally need to pursue a biologic pathway, such as:

• A 351(k) biosimilar application
• A 351(a) full biologics application
• Another FDA pathway supported by product-specific agency guidance

The practical development burden is higher than for a conventional generic injectable. The competitor must establish analytical similarity, manufacturing comparability, pharmacokinetic and pharmacodynamic performance, immunogenicity, and the suitability of the proposed formulation and delivery device.

What is the Orange Book and Purple Book status of Lyumjev?

Lyumjev’s regulatory position requires a distinction between legacy insulin listings and biologic reference-product records. The Orange Book historically listed insulin products approved as NDAs. Products approved or transitioned as biologics may be represented through the Purple Book framework and related FDA biological-product records.[5,6]

For diligence purposes, the relevant questions are:

1. Is Lyumjev listed as a reference product in the Purple Book?
2. Are any applicable patents listed in the FDA patent database or legacy Orange Book records?
3. What exclusivity period applies to the reference product?
4. Has FDA accepted any biosimilar application referencing insulin lispro-aabc?
5. Are the relevant claims directed to the insulin molecule, formulation, method of use, or device?

Patent and exclusivity status should be assessed separately. Regulatory exclusivity can expire before formulation or method patents, and issued patents may extend beyond the end of data or market exclusivity.

When does Lyumjev lose exclusivity?

Lyumjev’s U.S. approval date was June 2020. A biologic reference product generally receives 12 years of reference-product exclusivity from first licensure under the Public Health Service Act, subject to statutory rules and the product’s regulatory classification.[5]

That framework places the nominal reference-product exclusivity endpoint around 2032. The commercial launch date of a biosimilar can still be later because of:

• Formulation and device patents
• Method-of-use patents
• Patent litigation
• Settlement agreements
• FDA review timing
• Manufacturing validation
• Interchangeability requirements
• Pediatric exclusivity or other statutory extensions

The practical loss-of-exclusivity date is therefore determined by the later of regulatory availability and freedom to operate. A competitor that avoids Lilly’s absorption-enhancement claims may reach the market before a competitor attempting to reproduce the Lyumjev formulation.

Which companies are challenging or positioned to compete with Lyumjev?

Lyumjev competes in the ultra-rapid and rapid-acting insulin segment. Relevant products include:

Product	Sponsor	Differentiation
Lyumjev	Eli Lilly	Insulin lispro-aabc with rapid-absorption formulation
Humalog	Eli Lilly	Conventional insulin lispro
Fiasp	Novo Nordisk	Faster-acting insulin aspart formulation
NovoLog/NovoRapid	Novo Nordisk	Conventional insulin aspart
Apidra	Sanofi	Insulin glulisine
Admelog	Sanofi and partners	Follow-on insulin lispro
Generic insulin lispro	Multiple manufacturers	Lower-cost follow-on versions of lispro

Fiasp is the closest commercial comparator because it also uses formulation technology to accelerate absorption. The competitive distinction is therefore based on time-action profile, pump and pen availability, formulary placement, price, patient switching, and evidence in postprandial control.

A future Lyumjev biosimilar or follow-on competitor would need to compete against both Lilly’s intellectual property and entrenched rapid-acting insulin products.

How does Lyumjev compare with Fiasp from an excipient perspective?

Lyumjev and Fiasp use different insulin analogs and different formulation strategies.

Attribute	Lyumjev	Fiasp
Insulin analog	Insulin lispro	Insulin aspart
Absorption approach	Citrate and treprostinil-based formulation strategy	Formulation using absorption-enhancing components, including niacinamide
Sponsor	Eli Lilly	Novo Nordisk
Primary commercial claim	Faster early absorption and mealtime flexibility	Faster onset relative to conventional insulin aspart
Main follow-on barrier	Treprostinil-containing formulation and related claims	Niacinamide-containing formulation and related claims
Device relevance	Pens, vials, cartridges, pumps	Pens, vials, cartridges, pumps

The excipient strategies are not interchangeable. A company developing a follow-on product cannot assume that a successful Lyumjev formulation can be substituted into an insulin aspart product, or that Fiasp’s absorption technology provides a direct design-around.

What commercial opportunities exist for excipient suppliers?

Specialty excipient supply

The strongest direct opportunity is supply of high-purity treprostinil, citrate, and controlled-grade ancillary excipients. The supplier must support pharmaceutical quality agreements, change-control discipline, regulatory documentation, and long-term capacity.

Treprostinil offers the highest strategic value because it is less commoditized and is more closely associated with Lyumjev’s performance.

Analytical and formulation services

Contract development organizations can support:

• Insulin aggregation studies
• Subvisible-particle analysis
• Size-exclusion chromatography
• Reverse-phase and ion-exchange methods
• Bioassays and potency testing
• In-vitro release and diffusion testing
• Protein adsorption studies
• Extractables and leachables programs
• Pump-reservoir stability
• Container-closure integrity

These services are valuable to biosimilar developers because the formulation must be comparable without copying every element of the reference product.

Alternative absorption enhancers

A company could develop an alternative to treprostinil that provides a similar early pharmacokinetic profile. Candidate strategies may include:

• Other local vasodilatory excipients
• Permeation enhancers
• Modified buffering systems
• Surfactant systems
• Microenvironmental pH control
• Novel depot-disrupting excipients
• Device-assisted delivery

The regulatory risk is substantial. A new absorption enhancer can change local tolerability, immunogenicity, injection-site reactions, and systemic exposure. The opportunity is strongest for a formulation that improves absorption without requiring a new proprietary insulin sequence.

Device-compatible formulation platforms

Lyumjev’s use in pumps creates demand for formulations with strong in-use stability and low interaction with reservoir materials. Suppliers can compete through:

• Low adsorption to plastic surfaces
• Reduced aggregation under agitation
• Improved temperature stability
• Longer in-pump use periods
• Lower occlusion risk
• Compatibility with automated insulin-delivery systems

A formulation with better pump performance could generate commercial value even if its injection pharmacokinetics are similar to Lyumjev.

What manufacturing and intellectual-property barriers affect generic entry?

The primary barriers are protein manufacturing and formulation comparability, not the availability of individual excipients.

A follow-on developer must control:

• Recombinant insulin production
• Correct folding and disulfide-bond formation
• Desamido and other degradation products
• High-molecular-weight species
• Particulate matter
• Potency and receptor binding
• Sterility and endotoxins
• Preservative concentration
• pH and osmolality
• Container-closure performance
• Pen and pump dose accuracy

The excipient system can also create a patent barrier. A competitor may avoid the exact citrate-treprostinil combination but lose Lyumjev’s early-absorption profile. If it keeps the profile, it may risk formulation or method-of-use claims.

What generic launch scenarios exist for Lyumjev?

Scenario 1: Biosimilar using the same absorption-enhancing concept

This path offers the closest clinical match but presents the highest patent and regulatory exposure. The developer would seek analytical and clinical similarity while assessing claims around citrate, treprostinil, concentration ranges, and administration methods.

Scenario 2: Follow-on insulin lispro without Lyumjev’s absorption enhancers

This approach may reduce patent risk but would likely compete more directly with Humalog and Admelog than with Lyumjev. The product could receive lower pricing but would not provide the same ultra-rapid positioning.

Scenario 3: Alternative ultra-rapid formulation

A different excipient platform could avoid composition claims and offer independent clinical differentiation. Development costs and clinical uncertainty would be higher, but the product could obtain a stronger freedom-to-operate position.

Scenario 4: Device-led product

A company could focus on pump compatibility, automated delivery, or a more convenient pen while using a conventional rapid-acting insulin. This strategy shifts value from excipient IP to device and human-factors IP.

How strong is Lyumjev’s patent estate?

Lyumjev’s estate is strongest where formulation composition, absorption enhancement, and clinical use overlap. The commercial strength depends on claim breadth, remaining patent term, validity challenges, and whether the claims cover the product as marketed or only particular concentration ranges.

The estate is weaker against:

• A non-infringing insulin lispro formulation
• A different absorption-enhancing excipient
• A product with a materially different label
• A formulation that achieves rapid onset through device engineering
• A biosimilar that avoids protected method-of-use language

The highest-value diligence work is claim-charting each issued patent against the commercial formulation, device presentation, and proposed competing product. Patent family age alone does not establish blocking power.

What revenue exposure could Lyumjev face from follow-on competition?

Lyumjev competes in a large insulin market, but revenue exposure is product-specific. The principal risks are:

• Formulary substitution
• Rebates and net-price erosion
• Switching to Fiasp or conventional insulin lispro
• Biosimilar entry after reference-product exclusivity
• Lower-cost follow-on insulin products
• Insulin pump coverage changes
• Reduced willingness to pay for ultra-rapid onset

A follow-on product does not need to replicate all Lyumjev attributes to affect revenue. A lower-priced insulin lispro product can pressure Lilly’s portfolio by shifting patients away from Humalog, while a technically similar ultra-rapid product would threaten Lyumjev more directly.

Key Takeaways

• Lyumjev’s central formulation innovation is rapid absorption of insulin lispro-aabc through citrate and treprostinil-related technology.
• Treprostinil is the most commercially distinctive excipient and the most difficult component to replicate at pharmaceutical quality.
• Conventional excipients such as glycerol, metacresol, zinc, magnesium, and tromethamine support stability and multidose presentation but offer limited standalone differentiation.
• Lyumjev is a biologic insulin product, so biosimilar or follow-on competition is more relevant than a conventional ANDA generic.
• The nominal 12-year biologic reference-product exclusivity framework points to the early 2030s, but formulation, method-of-use, device, and litigation issues can extend practical market protection.
• The best supplier opportunities are specialty-grade treprostinil, analytical characterization, protein-stability testing, device compatibility, and alternative absorption-enhancer platforms.
• A non-infringing competitor that omits Lyumjev’s absorption technology may compete on price but would not necessarily match its ultra-rapid clinical profile.
• Fiasp is the closest competitive benchmark because it also uses an excipient-driven rapid-absorption strategy.

FAQs about Lyumjev excipients and market entry

Does Lyumjev contain treprostinil?

Lyumjev’s rapid-absorption technology is associated with treprostinil and citrate. The FDA prescribing information identifies the product’s formulation components and describes its accelerated absorption profile.[1]

Can a company make a generic version of Lyumjev?

A conventional small-molecule generic pathway is generally not the expected route. A competitor would more likely pursue a biosimilar or another biologic pathway, depending on FDA classification and product-specific regulatory requirements.

Is citrate a patentable excipient in Lyumjev?

Citrate itself is a long-established pharmaceutical excipient. Protection is more likely to arise from its use in a defined insulin formulation, concentration range, combination with another absorption enhancer, or method of administration.

What is the most difficult Lyumjev excipient to source?

Treprostinil is the most specialized component because it requires pharmaceutical-grade manufacturing, impurity control, regulatory documentation, and compatibility with a sensitive protein formulation.

Can an alternative excipient replace treprostinil?

Potentially, but the substitute would need to demonstrate comparable absorption, stability, tolerability, and clinical performance. It would also require a separate freedom-to-operate analysis and regulatory development strategy.

References

1. U.S. Food and Drug Administration. (2024). Lyumjev (insulin lispro-aabc) prescribing information. Eli Lilly and Company.

2. U.S. Food and Drug Administration. (2020). Clinical pharmacology review: Lyumjev (insulin lispro-aabc). Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2020, June 15). FDA approves Lyumjev, a new rapid-acting insulin for diabetes. U.S. Department of Health and Human Services.

4. Eli Lilly and Company. (2024). Lyumjev approved labeling and pediatric use information. Eli Lilly and Company.

5. U.S. Food and Drug Administration. (2020). Transition of insulin products and other biological products under the Public Health Service Act. U.S. Department of Health and Human Services.

6. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.